Tang B - Search Results

1

Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial.

Tang B, Chen Y, Jiang Y, Fang M, Gao Q, Ren X, Yao L, Huang G, Chen J, Zhang X, Li R, Zhao S, Gao M, Luo R, Qi M, Li F, Zheng F, Lee M, Tao X, Duan R, Guo J, Chi Z, Cui C. Tang B, et al. J Immunother Cancer. 2024 Oct 4;12(10):e009662. doi: 10.1136/jitc-2024-009662. J Immunother Cancer. 2024. PMID: 39366752 Free PMC article. Clinical Trial.

2

A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients.

Mao L, Si L, Chi Z, Cui C, Sheng X, Li S, Tang B, Guo J. Mao L, et al. Among authors: tang b. Eur J Cancer. 2011 Jul;47(10):1498-503. doi: 10.1016/j.ejca.2011.03.019. Epub 2011 Apr 13. Eur J Cancer. 2011. PMID: 21493058 Clinical Trial.

3

Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.

Lian B, Si L, Cui C, Chi Z, Sheng X, Mao L, Li S, Kong Y, Tang B, Guo J. Lian B, et al. Among authors: tang b. Clin Cancer Res. 2013 Aug 15;19(16):4488-98. doi: 10.1158/1078-0432.CCR-13-0739. Epub 2013 Jul 5. Clin Cancer Res. 2013. PMID: 23833309 Clinical Trial.

4

[Impact of sequential targeted therapy on progression-free survival in metastatic renal cell carcinoma].

Si L, Bai X, Mao L, Wang X, Chi Z, Cui C, Sheng X, Tang B, Guo J. Si L, et al. Among authors: tang b. Zhonghua Yi Xue Za Zhi. 2014 Sep 9;94(33):2580-3. Zhonghua Yi Xue Za Zhi. 2014. PMID: 25511488 Chinese.

5

Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients.

Sheng X, Li S, Chi Z, Si L, Cui C, Mao L, Lian B, Tang B, Wang X, Yan X, Kong Y, Dai J, Guo J. Sheng X, et al. Among authors: tang b. Br J Ophthalmol. 2015 Jul;99(7):990-6. doi: 10.1136/bjophthalmol-2014-305730. Epub 2015 Jan 16. Br J Ophthalmol. 2015. PMID: 25595173

6

Chemotherapy, biochemotherapy and anti-VEGF therapy in metastatic mucosal melanoma.

Cui C, Tang B, Guo J. Cui C, et al. Among authors: tang b. Chin Clin Oncol. 2014 Sep;3(3):36. doi: 10.3978/j.issn.2304-3865.2014.07.02. Chin Clin Oncol. 2014. PMID: 25841462 Free article.

7

[A pilot study of sunitinib as first-line therapy for metastatic renal cell carcinoma on a 2 weeks on/1 week off intermittent dosing schedule].

Cui C, Li S, Chi Z, Si L, Sheng X, Mao L, Lian B, Wang X, Tang B, Guo J. Cui C, et al. Among authors: tang b. Zhonghua Zhong Liu Za Zhi. 2015 May;37(5):375-8. Zhonghua Zhong Liu Za Zhi. 2015. PMID: 26463030 Chinese.

8

[Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma].

Tang B, Chi Z, Sheng X, Cui C, Si L, Kong Y, Li S, Mao L, Lian B, Wang X, Yan X, Guo J. Tang B, et al. Zhonghua Yi Xue Za Zhi. 2015 Aug 11;95(30):2459-61. Zhonghua Yi Xue Za Zhi. 2015. PMID: 26711209 Chinese.

9

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.

Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, Wang X, Yan X, Guo J. Sheng X, et al. Among authors: tang b. Oncotarget. 2016 May 10;7(19):27044-54. doi: 10.18632/oncotarget.7395. Oncotarget. 2016. PMID: 26894858 Free PMC article.

10

GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis.

Sheng X, Kong Y, Li Y, Zhang Q, Si L, Cui C, Chi Z, Tang B, Mao L, Lian B, Wang X, Yan X, Li S, Dai J, Guo J. Sheng X, et al. Among authors: tang b. Eur J Cancer. 2016 Sep;65:156-63. doi: 10.1016/j.ejca.2016.06.019. Epub 2016 Aug 4. Eur J Cancer. 2016. PMID: 27498141

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,308 results

Search Page

Filters